Skip Ribbon Commands
Skip to main content
Menu

Current Clinical Trials

​For enquiries, please email [email protected]

Phase 1


No Site​ ​Stage of cancer Title of study ​Principal investigator ​Details of trial ​Status
1
​All Solid Tumour​​Advanced recurrentTAPISTRY
Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational For You (TAPISTRY) Phase II Platform Trial
​Dr Tira TanNCT04589845Open
2
​All solid tumours
​Prior IO responders
​BAYER 21820
First-in-human dose-escalation and expansion study of the anti-CCR8 antibody BAY 3375968 in combination with pembrolizumab to evaluate the safety, tolerability, and pharmacokinetics in participants with selected advanced solid tumors
​Dr Tira Tan
NCT05537740
​Open
3
​All solid tumours​KRAS G12Cmut
RMC-6291-001
Phase 1/1b, Multicenter, Open-Label, Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects with Advanced KRASG12C Mutant Solid Tumors
​Dr Daniel TanNCT05462717​On hold
4
​NSCLC, PDAC and GC
Advanced recurrent
EBC-129-01
A Phase 1A/B Study To Evaluate The Safety And Tolerability Of EBC-129 As A Single Agent And In Combination With Pembrolizumab In Advanced Solid Tumours

​Dr Matthew Ng
NCT05701527
Open
​5
​NSCLC/ all solid tumours
​ ROS-1 positive
​NVL-520-01
A Phase 1/2 Study of the Highly Selective ROS1 Inhibitor NVL-520 in Patients with Advanced NSCLC and Other Solid Tumors (ARROS-1)

​Dr Daniel Tan
NCT05118789
​Open
​6
​HNSCC
​Advanced or recurrent
​ALE.CO4.01 
Phase I/II, Open-Label, Multi-Center Study of ALE.C04 (anti-Claudin-1 Antibody) as a Single Agent and in Combination with Pembrolizumab (anti- PD-1 antibody) in Adult Patients with Recurrent or Metastatic (R/M) Head and Neck Squamous Cell Carcinoma

​Dr Darren Lim
NCT06054477
​Open
7
​All solid tumors
​​SMARCA4 mutation
PRT3789-01 
A Phase 1 Open-Label, Multi-Center, Safety and Efficacy Study of PRT3789 in Participants with Select Advanced or Metastatic Solid Tumors with a SMARCA4 Mutation

​​Dr Daniel Tan


NCT05639751
​Open
8
​​NSCLC / lung, all solid tumours
​Advanced recurrent
​NVL-655-01
A Phase 1/2 Study of the Selective Anaplastic Lymphoma Kinase (ALK) Inhibitor NVL-655 in Patients with Advanced NSCLC and Other Solid Tumors (ALKOVE-1) 

​Dr Aaron Tan



NCT05384626
​Open
9
​Pancreatic / GI
​Advanced, Metastatic  / stage 4 / stage IV
​PAUF-I
A First in human, Phase 1/2a, Multicentre, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of PBP1510 in Patients with Advanced/Metastatic Pancreatic Cancer

​Dr David Tai
NCT05141149
​Open
​10
​Breast
​Advanced, Metastatic  / stage 4 / stage IV
CAAA603D12101
A Phase I/II, open-label, multi-center trial of [177Lu]Lu-NeoB in combination with capecitabine in adult patients with gastrin releasing peptide receptor positive, estrogen receptor-positive, human epidermal growth receptor-2 negative metastatic breast cancer after progression on previous endocrine therapy in combination with a CDK4/6 inhibitor 
Dr Yap Yoon Sim​NCT06247995
​Open
​11
​Ovarian, lung, breast, endometrial
​Advanced, Metastatic  / stage 4 / stage IV
​PMV-586-101
A Phase 1/2 Open-label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of PC14586 in Patients with Advanced Solid Tumors Harboring a p53 Y220C Mutation (PYNNACLE)

​Dr Tira Tan
NCT04585750
​Open
​12
​Ovarian, Endometrial and Lung adenocarcinoma
​Advanced, Metastatic  / stage 4 / stage IV
ZWI-ZW191-101
A Phase 1, Open-label, Multicenter, Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Ascending Doses of a Novel Folate Receptor Alpha Inhibitor, ZW191, as Monotherapy in Participants with Advanced Solid Tumors

​Dr Daniel Tan
NCT06555744
​Open
13
Squamous Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma, Esophageal Squamous Cell Carcinoma, Cervical Cancer
Advanced, Metastatic  / stage 4 / stage IV
ALE.P02.01
A Phase I/II, Open-Label, Multicenter Study of ALE.P02 (Claudin-1 Targeted Antibody-Drug Conjugate) as a Monotherapy in Adult Patients with selected CLDN1+ solid tumors

Dr Darren Lim
NCT06747585

Open

 

Current clinical trials by body parts

No Site​ ​Stage of cancer ​Title of study ​Principal investigator Details of trial Status
​1
​Biliary Tract / GI
​Advanced 1st line
​TOURMALINE D4191C00140
A Phase IIIb, Single Arm, Open-label, Multicentre Study of Durvalumab in Combination with Chemotherapy for the First Line Treatment for Patients with Advanced Biliary Tract Cancers 
​Dr David Tai
NCT05771480
On hold
​2
​Bladder / GU
​Metastatic
​SGNDV-001
An Open-label, Randomized, Controlled Phase 3 Study of Disitamab Vedotin in Combination with Pembrolizumab Versus Chemotherapy in Subjects with Previously Untreated Locally Advanced or Metastatic Urothelial Carcinoma that Expresses HER2 (IHC 1+ and Greater)
​Dr Ravindran Kanesvaran
NCT05911295
​Open
3
Breast
​Mets TNBCBEXMET
Metastatic Triple-Negative Taxane-Resistant Breast Cancer: Investigating the Role of Bexarotene in Inducing Susceptibility to Chemotherapy by Differentiating Cancer Cells from a Mesenchymal-Like to an Epithelial-Like Phenotype
​Dr Elaine Lim​NCT04664829​Open
4
​Breast
​Mets ER+PR+LaPemERLA
Lenvatinib and Pembrolizumab in Endocrine Resistant Breast Cancer with Letrozole in the Advanced setting – a Phase II Study
​Dr Yap Yoon SimNCT05286437​Open
5
​Breast​Mets ER+PR+ELEVATE
A Phase II randomized trial of Endocrine therapy Letrozole and Lenvatinib versus Fulvestrant in Metastatic Estrogen Receptor positive, HER2 negative breast cancer, who have progressed on CDK4/6 inhibitors
​Dr Elaine LimNCT05181033​Open
6
​Breast
​Mets HER2+/ PIK3CA mutant
​INAVO122:
A Phase III, Multicenter, Randomized, Double-blind, Placebo-controlled Study evaluating the Efficacy and Safety of Inavolisib in Combination with Phesgo versus Placebo in Combination with Phesgo after First Line Induction Therapy in Participants with PIK3CA-mutated HER2-positive Locally Advanced or Metastatic Breast Cancer
​Dr Yap Yoon Sim
NCT05894239

​Open
​7
​Breast
​early stage I-III TNBC or HR/HER2 low
​TROPION-Breast04: 
A Phase III, Open-label, Randomised Study of Neoadjuvant Datopotamab Deruxtecan (Dato‑DXd) Plus Durvalumab and Adjuvant Durvalumab With or Without Chemotherapy Versus Neoadjuvant Pembrolizumab Plus Chemotherapy and Adjuvant Pembrolizumab With or Without Chemotherapy for the Treatment of Adult Patients with Untreated Triple-Negative or HR‑low/HER2-negative Breast Cancer

​Dr Rebecca Dent
NCT06112379
​Open
​8
​Breast
​Mets HER2-/HR+ 
1L Hormone resistant

CO44657
A phase III randomized, open-label study evaluating efficacy and safety of giredestrant compared with fulvestrant, both combined with a CDK4/6 inhibitor, in patients with Estrogen Receptor-positive, HER2-negative advanced breast cancer with resistance to prior adjuvant endocrine therapy
​Dr Yap Yoon Sim
NCT06065748
​Open
​9
​Breast
​ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
​J2J-MC-JZLH / EMBER-4
A Randomized, Open-Label, Phase 3 Study of Adjuvant Imlunestrant vs Standard Adjuvant Endocrine Therapy in Patients who have Previously Received 2 to 5 years of Adjuvant Endocrine Therapy for ER+, HER2- Early Breast Cancer with an Increased Risk of Recurrence
​Dr Yap Yoon Sim
NCT05514054
​Open
​10
​Breast
​early stage I-III TNBC with Residual disease
MK-2870-012
A Phase 3, Randomized, Open-label, Study to Compare the Efficacy and Safety of Adjuvant MK-2870 in Combination with Pembrolizumab (MK-3475) Versus Treatment of Physician’s Choice in Participants With Triple Negative Breast Cancer (TNBC) Who Received Neoadjuvant Therapy and Did Not Achieve a Pathological Complete Response (pCR) At Surgery
​Dr Rebecca Dent
NCT06393374
​Open
​11
​Cervical
​metastatic
MK2870-20
A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-Line or Third-Line Treatment for Participants with Recurrent or Metastatic Cervical Cancer
​Dr Chay Wen Yee
NCT06459180
​Open
12
​CRC / Colorectal / GI
​NeoadjuvantOTSP-WoOCRC / MK-3475-886
Window of Opportunity Study with Neoadjuvant Pembrolizumab in MSS & MSI Colorectal Cancer
​Dr Iain Tan NCT03984578​Open
13
​Gastric GEJ / GI
​Advanced 2nd and 3rd line
ASPEN-06
A Phase 2/3 Study of ALX148 In Patients with Advanced HER2-Overexpressing Gastric/Gastroesophageal Junction Adenocarcinoma
​Dr Matthew Ng
NCT05002127
​On hold
​14
​Gastric GEJ / GI
​​2L/3L Adv/Metastatic
D9800C00001/CLARITY-PanTumour01
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2. (AZD0901)
​Dr Matthew Ng
NCT06219941
​Open
15
Liver cancer or Colorectal cancer with liver metastases / GI​AdjuvantCA209-7R9
An open label, single-arm, Phase II Neoantigen (NA) Dendritic Cell (DC) vaccine and anti-PD1 (Nivolumab) as adjuvant treatment in resected hepatocellular carcinoma (HCC) (Group A) and liver metastases from colorectal cancer (CRLM) (Group B)
​Dr Koo Si LinNCT04912765​Open
16
​​Liver / GI
​Locally advanced
​AHCC09
A Multinational, Double-blind, Placebo-Controlled, Parallel Randomized Arms, Phase II trial to Compare the Safety and Efficacy of Selective Internal Radiation Therapy (Y-90 resin microspheres) followed by Atezolizumab plus Bevacizumab versus Selective Internal Radiation Therapy (SIRT-Y90) followed by placebo in patients with locally advanced Hepatocellular Carcinoma
​Dr Toh Han Chong
NCT05377034
​Open
17
​​Liver / GI
​Resectable HCC (high risk of recurrence)
AHCC12
Deep, Multi-omics Phenotyping to Predict Response, Resistance and Recurrence to Adjuvant Atezolizumab plus Bevacizumab in Resected Hepatocellular Carcinoma (HCC)
​Dr Toh Han ChongNCT05516628​Open
18
​NSCLC / Lung
​Locally Advanced, Unresectable, Stage III / stage 3 NSCLC 
​BO42777 (HORIZON01)
A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)
​Dr Darren Lim
NCT05170204

​Open
19
​NSCLC / Lung
​locally advanced / metastatic / Mets NSCLC, stage 4/ stage IV BGB-LC-201
A Phase 2, Open-label, Multi-arm Study of Tislelizumab in Combination with Investigational Agents With or Without Chemotherapy in Patients with Previously Untreated, Locally Advanced, Unresectable, or Metastatic Non-Small Cell Lung Cancer
​Dr Darren LimNCT05635708​Open
​20
NSCLC / Lunglocally advanced / metastatic / Mets NSCLC, stage 4/ stage IV 
FURMO 004
AN OPEN-LABEL STUDY TO INVESTIGATE THE EFFICACY AND SAFETY OF FURMONERTINIB COMPARED TO PLATINUM-BASED CHEMOTHERAPY AS FIRST-LINE TREATMENT FOR PATIENTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER WITH EPIDERMAL GROWTH FACTOR RECEPTOR EXON 20 INSERTION MUTATIONS
Dr Gillianne Lai
NCT05607550
​Open
21
​NSCLC / Lung
​Mets NSCLC
SOS-1 / IIT-SIN-S1-2022-001
A Phase 2 Study of Osimertinib and S-1 in Treatment Resistant EGFR mutant NSCLC
​Dr Darren Lim
NCT05773092
​Open
22
​NSCLC / Lung
​Mets NSCLC
BI 1479-0008 (BEAMION LUNG-02)
A Phase III, open-label, randomized, active-controlled, multi-centre trial evaluating orally administered BI 1810631 compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations

​Dr Stephanie Saw
NCT06151574
​Open
​23
​NSCLC / Lung
​Mets NSCLC
HMBD-001-103
A Phase 1b Study to Evaluate HMBD-001 in Combination with Docetaxel with or without Cetuximab in Participants with Advanced Squamous Non-Small Cell Lung Cancers
​Dr Aaron Tan
NCT05910827
​Open
​24
​NSCLC / Lung
​Mets NSCLC
​A Phase III, Randomised, Open-Label Study of Savolitinib in Combination With Osimertinib Versus Platinum-Based Doublet Chemotherapy in Participants With EGFR Mutated MET-Overexpressed and/or Amplified, Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Progressed on Treatment With Osimertinib (SAFFRON)
​Dr Stephanie Saw
NCT05261399
​Open
​25
​SCLC / Lung
​Limited-Stage Small-Cell Lung Cancer 
​20230016  
A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Tarlatamab Therapy in Subjects With Limited-Stage Small-Cell Lung Cancer (LS-SCLC) who Have not Progressed Following Concurrent Chemoradiation Therapy (DeLLphi-306)
​Dr Amit Jain
NCT06117774
​Open
​26
​NSCLC / Lung
​locally advanced / metastatic / Mets NSCLC, stage 4/ stage IV
TAS6417-301 
An Open-Label, Randomized Phase 3, Global Multi-Center Trial to Assess the Efficacy and Safety of Zipalertinib (TAS6417) plus Pemetrexed and Cisplatin or Carboplatin, versus Pemetrexed and Cisplatin or Carboplatin, in Patients with Previously Untreated, Locally Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer (NSCLC) with Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations (REZILIENT3)
​Dr Gillianne Lai
NCT05973773
​Open
​27
​NSCLC / Lung
​Mets NSCLC
LUNAR-2 EF-44 
Pivotal, Randomized, Open-Label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant with Pembrolizumab and Platinum Based Chemotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer
​Dr Ng Quan Sing
NCT06216301
​Open
​28
​NSCLC / Lung
​Advanced NSCLC
20230153 
Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of AMG 193 in Subjects with methylthioadenosine phosphorylase (MTAP)-deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)
​Dr Darren Lim
NCT06593522
​Open
​29
​NSCLC / Lung
​II to IIIB (N2) NSCLC
V940-009
A Phase 3 Randomized Double-blind Study of Adjuvant Pembrolizumab With or Without V940 in Participants With Resectable Stage II to IIIB (N2) NSCLC not Achieving pCR After Receiving Neoadjuvant Pembrolizumab With Platinum-based Doublet Chemotherapy (INTerpath-009)

​Dr Aaron Tan
NCT06623422
​Open
30
​Lymphoma
​Relapsed/ Refractory B-cell lymphoma
MK2140-006
A Multicenter, Open-label, Phase 2 Basket Study to Evaluate the Safety and Efficacy of MK-2140 as a Monotherapy and in Combination in Participants With Aggressive and Indolent B-cell Malignancies
​Dr Tan Ya Hwee
NCT05458297
​Open
31
​Lymphoma
​relapsed/ refractory Lymphoma
​POLAR
Pembrolizumab and Olaparib Treatment for Relapsed or Refractory Peripheral T-Cell Lymphoma (POLAR)

​Dr Lim Soon Thye
NCT06160843
​Open
​32
​Lymphoma
​Untreated DLBCL
​R1979-ONC-2105
A Phase 3, Open label, Randomized Study Comparing the Efficacy and Safety of Odronextamab (REGN1979), an anti CD20 × anti-CD3 bispecific antibody, in Combination with CHOP (O-CHOP) versus Rituximab in combination with CHOP (R-CHOP) in Previously Untreated Participants with Diffuse Large B-cell Lymphoma (DLBCL) (OLYMPIA-3)
​Dr Ong Shin Yeu
NCT06091865
​Open
​33
​Lymphoma
​relapsed/ refractory lymphoma
​R1979-HM-2299
A Phase 3, Randomized, Open Label Study Evaluating the Efficacy and Safety of Odronextamab (REGN1979), an Anti-CD20 x Anti-CD3 Bispecific Antibody, versus Standard of Care Therapy in Participants with Relapsed/Refractory Aggressive B-cell non-Hodgkin Lymphoma (OLYMPIA-4)
​Dr Lawrence Ng
NCT06230224
​Open
34
​NPC​Metastatic, mets
SG-AAA-II-01 / CAAA601A0SG01T
A Biomarker Enrichment Phase II study of 177Lu-DOTATATE in Metastatic Nasopharyngeal Cancer with a safety run-in
​Dr Daniel TanNCT05198479​Open
35
​Ovarian
​Metastatic
STRO-002-GM2:
A phase II open-label study evaluating the efficacy and safety of STRO-002 in women with advanced, relapsed platinum resistant Epithelial Ovarian Cancer (including Fallopian Tube or Primary Peritoneal Cancers) expressing Folate Receptor alpha (FolRα)
​Dr Elaine Lim
NCT05870748
​Open
36
​Pancreas / GI
​Metastatic
LDOXIRI-PDAC-01
A phase II study of metronomic capecitabine, oxaliplatin and UGT1A1 genotype-directed irinotecan in metastatic pancreatic cancer patients
​Dr Joycelyn Lee
NCT05929885
​Open
​37
​Pancreas / GI
​Metastatic
D9800C00001/CLARITY-PanTumour01
A Phase II, Open-label, Multi-centre Study to Evaluate Safety, Tolerability, Efficacy, PK, and Immunogenicity of AZD0901 as Monotherapy and in Combination with Anti-cancer Agents in Participants with Advanced Solid Tumours Expressing Claudin 18.2. (AZD0901)
​Dr Matthew Ng
NCT06219941
​Open
​38
​Prostate
​Metastatic
​CAAA617D12302
An International, Prospective, Open-label, Multi-center, Randomized Phase III Study comparing lutetium (177Lu) vipivotide tetraxetan (AAA617) versus observation to delay castration or disease recurrence in adult male patients with prostate-specific membrane antigen (PSMA) positive Oligometastatic Prostate Cancer (OMPC)
​Dr Jeffery Tuan
NCT05939414
​Open
​39
​Prostate
​Metastatic/ mCRPC
​MK-5684-003
A Phase 3 Randomized, Open-label Study of MK-5684 versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration Resistant Prostate Cancer (mCRPC) Previously Treated With Next-generation Hormonal Agent (NHA) and Taxane-based Chemotherapy
​Dr Ravindran Kanesvaran
NCT06136624
​Open
40
​Prostate
​Metastatic/ mCRPC
MK5684-004
A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants with Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment with One Next-generation Hormonal Agent (NHA)
​Dr Johan Chan
NCT06136650
​Open
41
​Renal
​Locally advanced / metastatic - 1st line
​XL092-304
A Randomized Open-Label Phase 3 Study of XL092 + Nivolumab vs Sunitinib in Subjects with Advanced or Metastatic Non-Clear Cell Renal Cell Carcinoma
​Dr Ravindran Kanesvaran
NCT05678673
​Open


General

​No Site​ ​Stage of cancer ​Title of study ​Principal investigator ​Details of trial ​Status
1
​SOLID TUMORS​​LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line OnwardsAPL10101 
Phase 1/2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
​Dr Gillianne LaiNCT03175224​Open
2​SOLID TUMORS​​LOCALLY ADVANCED/ METASTATIC – 1st and 2nd Line OnwardsTPX-0005-01
A Phase 1/2, Open-Label, Multi-Center, First-In-Human Study of the Safety, Tolerability, Pharmacokinetics and Anti-Tumor Activity of TPX-0005 in Patients with Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 rearrangements (TRIDENT-1)
​Dr Darren LimNCT03093116Open
3
SOLID TUMORS
(currently only HCC and gastric cohorts are opened)

Advanced curatively unresectable solid tumors failing standard therapy.

HCC: must have failed at least 1 line of standard therapy

Gastric cancer: must have failed at least 2 line of standard therapy (inclusive of adjuvant treatment)

Other solid tumours: must have failed at least 1 line of standard therapy

NCCS-2018-Phase2-PRL3
An open label Phase II study of the efficacy and tolerability of PRL3-ZUMAB and predictive biomarkers in advanced solid tumours
​Dr Matthew Ng
NCT04118114​Open
4
​SOLID TUMORS
ADVANCED/ METASTATIC - 2nd Line
STCC-01
A phase II multi-centre study evaluating the efficacy of dacomitinib for patients with epidermal growth factor receptor (EGFR)-driven advanced solid tumours with low EGFR-AS1 lncRNA expression or other novel emerging biomarkers

Dr Daniel Tan
NCT04946968
​Open
5
​SOLID TUMORS
​ADVANCED/ METASTATIC
​Phase 2 Study to Evaluate the Efficacy and Safety of Belzutifan (MK-6482, formerly PT2977) Monotherapy in Participants With Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Advanced Solid Tumors With HIF-2α related Genetic Alterations
​Dr Joanne Ngeow
NCT04924075
Open